In contrast, Byrski et al. [1] offered an experimental treatment to those patients, who had a relatively good chances to be cured by already existing approaches; perhaps, the design of this neoadjuvant study could become a subject of harsh criticism if cisplatin failed to induce spectacular tumor responses in BRCA1 carriers. The gene discussed is BRCA1; the disease is neoplasm.